P.D. van Helden, E.G. Hoal/Comparative Immunology, Microbiology and Infectious Diseases 36(2013 )287-294 16 Keet DF, Michel AL, Bengis RG, Becker P, van Dyk DS, van Vuuren and protection against challenge with with Mycobacterium bovis. [36] Dey B, Jain R, G an VD, Tyagi AK. A 17 DN, Aldwell FE, Vordermeier HM, Hewinson RG, Buddle and confers enhanced protection against BM. Protection against bovine tuberculosis induced by oral vac- 2011:6:e23360. ination of cattle with My m bovis bcg is not enhanced [37] Sweeney KA. by co-administration of atis induces potent bactericidal immunity against [18] Maue AC, Waters WR, Pa /C, etal. An ESAT-6: CFPl0 DNA vaccine ad [38] Waters WR, Palmer MV, Nonnecke B]. Thacker TC, Scherer CFC, Estes with virulent M. bovis vaccine 2007: 25: 4735-46. [19 de Klerk L Michel AL Bengis RG, Kriek NPl, Godfroid ]. Be accination failed Iffer) against experimental intratonsillar challenge with Mycobac [39] Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Estes DM, et al. Efficacy and immunogenicity of Mycobac DeltaRD1 against aerosol M. bovis infection in neonat a [40] Desel C, Dorhoi ental BCG 21 Lopez-Valencia G, Renter ta T, Williams JdJ. stimulating ination of type l and type 17 cytokine the protective efficacy F Mycob vaccine [41] Zimmerman DM, Waters WR, Lyashchenko KP Nonn lin veterinary Science 2010: 88: [22] Cross ML Henderson R], Lambeth MR, Buddle BM, Aldwell FE sinc in domes tability, efficacy, and palatability to brushtail possums (Tri- 42]H ladle M. Pawlowski A Schroder U, williams A Hatch ecula)in New Zealand. Journal of wildlife Diseases ulosis arabinomannan-protein conju- cine2003;21:4081-9 23 Buddle BM, Aldwell FE, de Lisle GW, vordermeier HM, Hewinson [43] Haile M, Schroder U. Hamasur B, Pawlowski A, Jaxmar T, Kallenius RG, Wedlock DN. Low oral BCG doses fail to protect cattle again nization with heat-killed Mycobacterium bovis bacille an experimental challenge with Mycobacterium bovis. Tuberculosis Calmette-Guerin(BCG) in Eurocine L3 adjuvant protects against 4 Garrido JM, an-Beck B, Minguijon E, Ballesteros C, lindo RC, et al. Protection against tuberculosis in Eurasian wild edades Infecciosas y Microbiologia Clinica 2011; 29(SuppL. ONE2011:6:e24905 [45] Lahey T, Mitchell BK, Arbeit RD, ShethS, Matee M, Horsburgh CR, et al. [25 Palmer MV, Thacker TC, Waters WR. Vaccination of white-tailed deer protection (Odocoileus virginianus) with Mycobacterium bovis bacillus Calmette Guerin Vaccine 2007: 25: 6589-97 ion. PLos one 2011: 6 e22074. [26] Buddle BM, Wedlock DN, Denis M. Progress in the development of [46] Rahman S, Magalhaes L Rahman J. Ahmed RK Sizemore DR, Scanga tuberculosis vaccines for cattle and wildlife. Infection and immunit 2006:112:191-200 cytolytic T cell response 27 Larsen MH, Biermann K Chen B, Hsu T, Sambandamurthy VK, Lack infected primates. Molecular Medicine 2012: 18: 647-58. [47] Rook GA, Stanford JL The Koch phenom sis vaccine candidates in ogy of tuberculosis. Current Topics in Microbiology and Immunology 28 Capuano Sv, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, [48 Rodrigues LC, Mangtani P, Abubakar L How does the level of BCG vac- uman M. tuberculosis infection Infection and Immunity 2003: 71: [49] Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, induced by BCG vaccina 29 Lin PL Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quanti- [50] Stringer LA. Wilson PR, Heuer C, Hunnam JC. Mackintosh CG Effect of 30] Di Pietrantonio T, Correa JA, Orlova M, Behr MA, Schurr E. Joint paratuberculosis on specificity of diagne effects of host genetic background and mycobacterial pathog usceptibility to infection. Infection and Immunity 2011: 79 ulosis in farmed red deer(Cervus elaphus). New Zealand veterinary 372-8. [51] Yang X, Chen O, liY, wu S Mycobacterium vaccae as adjuvant ther- [52] Randor sis in Malawi. Karonga Prevention Trial Grou in human genetic susceptibility to tuberculosis Tuberculosis(Edin- [53] Tchilian EZ, Ronan EO, de Lara C, Lee IN, Franken KLMC, Vorde ant CI. Simkin L Black GF, Stanley K, Hughes J, PLOS ONE2011:6:e27477 hyperendemic for tuberculosis. Journal of Experimental Medicine [54] Kupferschmidt K. Taking a new shot at a TB vaccine. Science 4 Waters W, Palmer M, Buddle B, Vordermeier H Bovine tuberculo- [55 Walzl G, Ronacher K, Hanekom W, Scriba T). Zumla A Immuno- arkers of tubercu [35] Sun R, Skeiky YAW, Izzo A, Dheenadhayalan V, Imam Z, Pen [56] Weir RE, Black GF, Nazareth B, Floyd S. Stenson S, Stanley C, et al. E, et al. Novel recombinant BCG expressing perfringolysin O and The influence of previous exposure to environmental mycobacte- he over-expression of key immunodominant antigens: pre-clinical ria on the interferon-gamma response to Bacille Calmette-GuerinP.D. van Helden, E.G. Hoal / Comparative Immunology, Microbiology and Infectious Diseases 36 (2013) 287–294 293 [16] Keet DF, Michel AL, Bengis RG, Becker P, van Dyk DS, van Vuuren M, et al. Intradermal tuberculin testing of wild African lions (Pan￾thera leo) naturally exposed to infection with Mycobacterium bovis. Veterinary Microbiology 2010;144:384–91. [17] Wedlock DN, Aldwell FE, Vordermeier HM, Hewinson RG, Buddle BM. Protection against bovine tuberculosis induced by oral vac￾cination of cattle with Mycobacterium bovis BCG is not enhanced by co-administration of mycobacterial protein vaccines. Veterinary Immunology and Immunopathology 2011;144:220–7. [18] Maue AC, Waters WR, Palmer MV, Nonnecke BJ, Minion FC, Brown WC, et al.An ESAT-6:CFP10 DNAvaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle chal￾lenged with virulent M. bovis. Vaccine 2007;25:4735–46. [19] de Klerk L, Michel AL, Bengis RG, Kriek NPJ, Godfroid J. BCG vaccination failed to protect yearling African buffaloes (Syncerus caffer) against experimental intratonsilar challenge with Mycobac￾terium bovis. Veterinary Immunology and Immunopathology 2010;137:84–92. [20] Waters WR, Palmer MV, Nonnecke BJ, Thacker TC, Scherer CFC, Estes DM, et al. Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves. Vac￾cine 2009;27:1201–9. [21] Lopez-Valencia G, Renteria-Evangelista T, Williams JdJ, Licea￾Navarro A, Mora-Valle A De L, Medina-Basulto G. Field evaluation of the protective efficacy of Mycobacterium bovis BCG vaccine against bovine tuberculosis. Research in Veterinary Science 2010;88: 44–9. [22] Cross ML, Henderson RJ, Lambeth MR, Buddle BM, Aldwell FE. Lipid-formulated bcg as an oral-bait vaccine for tuberculosis: vaccine stability, efficacy, and palatability to brushtail possums (Tri￾chosurus vulpecula) in New Zealand. Journal of Wildlife Diseases 2009;45:754–65. [23] Buddle BM, Aldwell FE, de Lisle GW, Vordermeier HM, Hewinson RG, Wedlock DN. Low oral BCG doses fail to protect cattle against an experimental challenge with Mycobacterium bovis. Tuberculosis (Edinburgh) 2011;91:400–5. [24] Garrido JM, Sevilla IA, Beltrán-Beck B, Minguijón E, Ballesteros C, Galindo RC, et al. Protection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovis. PLoS ONE 2011;6:e24905. [25] Palmer MV, Thacker TC, Waters WR. Vaccination of white-tailed deer (Odocoileus virginianus) with Mycobacterium bovis bacillus Calmette Guerín. Vaccine 2007;25:6589–97. [26] Buddle BM, Wedlock DN, Denis M. Progress in the development of tuberculosis vaccines for cattle and wildlife. Infection and Immunity 2006;112:191–200. [27] Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lack￾ner AA, et al. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 2009;27:4709–17. [28] Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of cynomol￾gus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infection and Immunity 2003;71: 5831. [29] Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quanti￾tative comparisonof active andlatenttuberculosis inthe cynomolgus macaque model. Infection and Immunity 2009;77:4631. [30] Di Pietrantonio T, Correa JA, Orlova M, Behr MA, Schurr E. Joint effects of host genetic background and mycobacterial pathogen on susceptibility to infection. Infection and Immunity 2011;79: 2372–8. [31] Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clinical & Developmental Immunology 2011, http://dx.doi.org/10.1155/2011/405310. [32] MöllerM, Hoal EG.Currentfindings, challenges andnovel approaches in human genetic susceptibility to tuberculosis. Tuberculosis (Edin￾burgh) 2010;90:71–83. [33] Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, Hughes J, et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. Journal of Experimental Medicine 2009;206:2583–91. [34] Waters W, Palmer M, Buddle B, Vordermeier H. Bovine tuberculo￾sis vaccine research: historical perspectives and recent advances. Vaccine 2012;30:2611–22. [35] Sun R, Skeiky YAW, Izzo A, Dheenadhayalan V, Imam Z, Penn E, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with mycobacterium tuberculosis. Vaccine 2009;27:4412–23. [36] Dey B, Jain R, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS ONE 2011;6:e23360. [37] Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo Marcela, et al. A recombinant Mycobacterium smeg￾matis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nature Medicine 2011;17:1261–8. [38] Waters WR, Palmer MV, Nonnecke BJ, Thacker TC, Scherer CFC, Estes DM, et al. Failure of a Mycobacterium tuberculosis DeltaRD1 Delta￾panCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis Bacille Calmette Guerin. Vaccine 2007;25:7832–40. [39] Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalap￾athy KV, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immuno￾competent and immunocompromised mice against experimental tuberculosis. Vaccine 2006;24:6309–20. [40] Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SHE, et al. DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination oftype 1 and type 17 cytokine responses. Journal of Infectious Diseases 2011;204:1573–84. [41] Zimmerman DM, Waters WR, Lyashchenko KP, Nonnecke BJ, Arm￾strong DL, Jacobs Jr WR, et al. Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domes￾tic cats infected with feline immunodeficiency virus. Clinical and Vaccine Immunology: CVI 2009;16:427–9. [42] Hamasur B, Haile M, Pawlowski A, Schröder U, Williams A, Hatch G, et al. Mycobacterium tuberculosis arabinomannan–protein conju￾gates protect against tuberculosis. Vaccine 2003;21:4081–93. [43] Haile M, Schröder U, Hamasur B, Pawlowski A, Jaxmar T, Källenius G, et al. Immunization with heat-killed Mycobacterium bovis Bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 2004;22:1498–508. [44] Martín Montanés C, Gicquel B. New tuberculosis vaccines. Enfermedades Infecciosas y Microbiologia Clinica 2011;29(Suppl. 1):57–62. [45] Lahey T, Mitchell BK,Arbeit RD, Sheth S, Matee M, Horsburgh CR, et al. Polyantigenic interferon- responses are associated with protection from TB among HIV-infected adults with childhood BCG immuniza￾tion. PLoS ONE 2011;6:e22074. [46] Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8+ cytolytic T cell responses in lesions from Mycobacterium tuberculosis infected primates. Molecular Medicine 2012;18:647–58. [47] Rook GA, Stanford JL. The Koch phenomenon and the immunopathol￾ogy of tuberculosis. Current Topics in Microbiology and Immunology 1996;215:239–62. [48] Rodrigues LC, Mangtani P, Abubakar I. How does the level of BCG vac￾cine protection against tuberculosis fall over time? British Medical Journal 2011;343:d5974. [49] Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, et al. Persistence of the immune response induced by BCG vaccina￾tion. BMC Infectious Diseases 2008;8:9. [50] Stringer LA, Wilson PR, Heuer C, Hunnam JC, Mackintosh CG. Effect of vaccination and natural infection with Mycobacterium avium subsp. paratuberculosis on specificity of diagnostic tests for bovine tuber￾culosis in farmed red deer (Cervus elaphus). New Zealand Veterinary Journal 2011;59:218–24. [51] Yang X, Chen Q, Li Y, Wu S. Mycobacterium vaccae as adjuvant ther￾apy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS ONE 2011;6:e23826. [52] Randomised controlled trial of single BCG repeated BCG or combined BCG and killed Mycobacterium leprae vaccine for prevention of lep￾rosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996;348:17–24. [53] Tchilian EZ, Ronan EO, de Lara C, Lee LN, Franken KLMC, Vorder￾meier MH, et al. Simultaneous immunization against tuberculosis. PLoS ONE 2011;6:e27477. [54] Kupferschmidt K. Taking a new shot at a TB vaccine. Science 2011;334:1488. [55] Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immuno￾logical biomarkers of tuberculosis. Nature Reviews Immunology 2011;11:343–54. [56] Weir RE, Black GF, Nazareth B, Floyd S, Stenson S, Stanley C, et al. The influence of previous exposure to environmental mycobacte￾ria on the interferon-gamma response to Bacille Calmette-Guérin